The Enterprise Value as of November 2024 (TTM) for G1 Therapeutics, Inc. (GTHX) is 410.58M

According to G1 Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 410.58M. This represents a change of 176.09% compared to the average of 148.71M of the last 4 quarters.

G1 Therapeutics, Inc. (GTHX) Historical Enterprise Value (quarterly & annually)

How has GTHX Enterprise Value performed in the past?

The mean historical Enterprise Value of G1 Therapeutics, Inc. over the last ten years is 301.62M. The current 410.58M Enterprise Value has changed 13.51% with respect to the historical average. Over the past ten years (40 quarters), GTHX's Enterprise Value was at its highest in in the September 2018 quarter at 1.35B. The Enterprise Value was at its lowest in in the September 2023 quarter at -15116067.36.

G1 Therapeutics, Inc. (GTHX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of G1 Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

G1 Therapeutics, Inc. (GTHX) Average Enterprise Value

How has GTHX Enterprise Value performed in the past?

The current Enterprise Value of G1 Therapeutics, Inc. (GTHX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

G1 Therapeutics, Inc. (GTHX) Enterprise Value vs. Peers

How is GTHX’s Enterprise Value compared to its peers?

G1 Therapeutics, Inc.’s Enterprise Value is less than Allogene Therapeutics, Inc. (497.27M), greater than Heron Therapeutics, Inc. (315.25M), less than Annexon, Inc. (497.96M), greater than Sangamo Therapeutics, Inc. (380.78M), greater than X4 Pharmaceuticals, Inc. (38.44M), greater than HOOKIPA Pharma Inc. (-36166707.00), less than Mereo BioPharma Group plc (496.22M), greater than Galera Therapeutics, Inc. (-7482657.00), greater than Acumen Pharmaceuticals, Inc. (139.19M), greater than Atara Biotherapeutics, Inc. (54.85M), greater than Fate Therapeutics, Inc. (321.89M), less than Sana Biotechnology, Inc. (551.82M), greater than Caribou Biosciences, Inc. (177.59M), less than Arcus Biosciences, Inc. (1.20B), less than Day One Biopharmaceuticals, Inc. (963.46M), less than Blueprint Medicines Corporation (6.36B), less than Axsome Therapeutics, Inc. (4.65B), greater than PDS Biotechnology Corporation (53.10M), greater than Amylyx Pharmaceuticals, Inc. (291.98M), greater than Coherus BioSciences, Inc. (259.52M), greater than Larimar Therapeutics, Inc. (363.34M), greater than Puma Biotechnology, Inc. (166.37M), greater than MacroGenics, Inc. (57.83M),

Build a custom stock screener for G1 Therapeutics, Inc. (GTHX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like G1 Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

G1 Therapeutics, Inc. (GTHX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like G1 Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.